Botanical research centers
This article was originally published in The Tan Sheet
Executive Summary
NCCAM and NIH's Office of Dietary Supplements are co-funding five-year grants for five research centers investigating "a variety of widely consumed botanicals from flaxseed to tarragon," NCCAM Director Stephen Straus, MD, announces April 7. The Memorial Sloan-Kettering Cancer Center in New York will research botanicals that may modulate immune function, including echinacea and Chinese herbal formulations. Metabolic syndrome, obesity and diabetes are the focus of a partnership between Rutgers and Louisiana State University. Other study areas include anti-inflammatory actions of botanical lipids at Wake Forest and Harvard; women's health at the University of Illinois-Chicago; and age-related diseases at Purdue, Rutgers and the University of Alabama. First-year funding for all five combined totals about $6.75 mil...
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.